Sep 25, 2024 · The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.

Jan 23, 2024 · What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. The current shift focuses on enhancing their efficacy by addressing the crucial need for robust T cell responses, an apparent bottleneck for broader impact ...

Jan 16, 2025 · Streamlining macrocyclic therapeutic development Platforms such as PeptiDream’s drug discovery platform system 17 have facilitated easier synthesis and screening of macrocyclic peptide libraries for lead compounds (eg, the PD-L1 macrocycle from Figure 1). Another approach to macrocyclic library design is to generate pools of peptidic scaffolds that are designed to possess qualities such as ...

Sep 19, 2024 · In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.

Dec 12, 2024 · Discover how Novartis and PTC Therapeutics are working together to address the unmet medical need in Huntington's disease treatment.

Nov 1, 2024 · Scientists at the UK Dementia Research Institute, University of Cambridge, have identified a drug commonly used to treat glaucoma can protect against tau protein build-up in the brain in genetically engineered zebrafish and mice. They screened over 1,437 clinically-approved drug compounds and found that carbonic anhydrase inhibitors, of which the glaucoma drug methazolamide is one, remove tau ...

Aug 6, 2024 · What are the main therapeutic areas beyond oncology where ADCs show potential? A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. The development of ADCs in these areas is ongoing, with several preclinical ...

Dec 11, 2024 · The global small molecule drug discovery market is set for substantial growth, according to a report published by The Insight Partners this month. The report projects that the sector’s value will reach $106.77 billion by 2031, representing a compound annual growth rate of 9.7 percent, which highlights the increasing demand for small molecule therapeutics in the pharmaceutical industry. Small ...

Sep 25, 2024 · Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional re ...

Dec 16, 2024 · Nektar Therapeutics presented promising results at the 66th Annual ASH Meeting, showing that NKTR-255, an investigational IL-15 agonist, significantly boosts the complete response rate (CRR) in patients with relapsed/refractory large B-cell lymphoma (LBCL) after CD19-directed CAR-T therapy.